Hot-melt co-extrusion technology as a manufacturing platform for anti-hypertensive fixed-dose combinations

MLA

Shu Li, et al. “Hot-Melt Co-Extrusion Technology as a Manufacturing Platform for Anti-Hypertensive Fixed-Dose Combinations.” British Journal of Pharmacy, vol. 4, Apr. 2019. EBSCOhost, https://doi.org/10.5920/bjpharm.596.

APA

Shu Li, Zoe Senta-Loys, Anne Marie Healy, Gareth C. Gilvary, Ammar Almajaan, Yiwei Tian, David S. Jones, Gavin Andrews, & Jeremiah Kelleher. (2019). Hot-melt co-extrusion technology as a manufacturing platform for anti-hypertensive fixed-dose combinations. British Journal of Pharmacy, 4. https://doi.org/10.5920/bjpharm.596

Chicago

Shu Li, Zoe Senta-Loys, Anne Marie Healy, Gareth C. Gilvary, Ammar Almajaan, Yiwei Tian, David S. Jones, Gavin Andrews, and Jeremiah Kelleher. 2019. “Hot-Melt Co-Extrusion Technology as a Manufacturing Platform for Anti-Hypertensive Fixed-Dose Combinations.” British Journal of Pharmacy 4 (April). doi:10.5920/bjpharm.596.